The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma.

ABSTRACT:

Background

Antiangiogenic drugs have shown initial efficacy in the treatment of advanced thymic carcinomas (TCs); however, data are limited. In this study, we provide real-world data relating to the efficacy of antiangiogenic drugs for the treatment of patients with TCs.

Methods

We retrospectively collected data on clinical progress after first-line chemotherapy in TCs patients who were treated with small molecule antiangiogenic drugs at our institution between January 2010 and December 2021. Tumor response was evaluated according to version 1.1 of the Response Evaluation Criteria in Solid Tumors. Progression free survival and overall survival were calculated using the Kaplan-Meier method.

Results

Of the 17 patients enrolled, 13 (76.5%) received apatinib and four (23.

SUBMITTER: Guan Y 

PROVIDER: S-EPMC9817249 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature